For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ORGANIZATION
ORGANIZATION
- JGA Chief Sawai to Stay in His Post, Deputy Chief Tamura Stepping Down
June 4, 2020
- JPMA Reprimands Torii, Nippon Chemiphar over Price-Fixing
May 29, 2020
- JPMA to Compile Proposal for Measures against Infectious Diseases: Chief
May 29, 2020
- JPWA Resolution Urges Govt to Revisit Off-Year Drug Re-Pricing
May 29, 2020
- Generic/Biosimilar Society Calls on MHLW to Ensure Stable API Supply
May 26, 2020
- Japan Pharmacist Group Renews Opposition to Off-Year Re-Pricing in FY2021
May 22, 2020
- Pneumococcal Vaccination Rate in Children Falls Sharply amid COVID-19 Pandemic: Survey
May 21, 2020
- JCHO Hospitals to Switch from Joint to Separate Bidding for Drug Purchases after Bid-Rigging Scandal
May 21, 2020
- Don’t Give Hasty COVID-19 Nod for Existing Drugs, Follow Int’l Rules for Avigan Approval: JMA
May 21, 2020
- Hodanren Criticizes Zolgensma’s High NHI Price as “Result of a Money Game”
May 18, 2020
- FPMAJ to Continue COVID-19 Impact Survey on Drug Supplies
May 18, 2020
- Japan Pharmacist Group Opposes Off-Year Re-Pricing in FY2021
May 1, 2020
- PhRMA, EFPIA Issue Joint Statement on Air Transporting Critical Medicines amid COVID-19 Outbreak
April 30, 2020
- JMA Calls for Early Avigan Use in High-Risk Patients Hospitalized with COVID-19
April 30, 2020
- IFPW Postpones Tokyo General Meeting to October 2021
April 27, 2020
- SMA Patient Group Presses MHLW to Hasten Zolgensma Listing
April 17, 2020
- FPMAJ Ups Ante for Drug Supply Coordination amid COVID-19 Crisis
April 14, 2020
- EFPIA Japan Says No Drug Shortages for Now, but Warns of Fluid Situation
April 8, 2020
- JPMA to Vet Impact of Drug Pricing Reform, Make Proposals for R&D Tax Break System: FY2020 Project Plan
April 8, 2020
- Tohoku Medical Megabank, JPMA Initiate Joint Research on Preventive and Preemptive Health
April 2, 2020
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…